Eupraxia Pharmaceuticals Inc.: Wedbush initiates coverage with outperform rating; price target $17
EPRX•Wedbush initiated coverage of Eupraxia Pharmaceuticals with an outperform rating and a $17 price target.
Related News
Cronos Group hosts first Investor Day webcast
CRON•
SimilarWeb CEO Or Offer disposes of $529,934.14 in common shares
SMWB•
Immuneering MAPKeeper-301 Phase 3 pancreatic cancer trial abstract wins ESMO 2026 poster slot
IMRX•
Archer says HSR waiting period expires for planned purchase of Boeing units Wisk, Insitu and SkyGrid
ACHR•
Milestone Pharmaceuticals enrolls first Canadian patient in ReVeRA-301 Phase 3 AFib-RVR trial
MIST•